RESUMEN
Interactions of N2 at oxide surfaces are important for understanding electrocatalytic nitrogen reduction reaction (NRR) mechanisms. Interactions of N2 at the polycrystalline vanadium oxide/vapor interface were monitored at room temperature and total pressures up to 10-1 Torr using Near-Ambient Pressure X-ray Photoelectron Spectroscopy (NAP-XPS). The oxide film was predominantly V(IV), with V(III) and V(V) components. XPS spectra were acquired in environments of both pure N2 and equal pressures of N2 and H2O vapor. In pure N2, broad, partially resolved N1s features were observed at binding energies of 401.0 and 398.7 eV, with a relative intensity of â¼3:1, respectively. These features remained upon subsequent pumpdown to 10-9 Torr. The observed maximum N surface coverage was â¼1.5 × 1013 cm-2-a fraction of a monolayer. In the presence of equal pressures of H2O, the adsorbed N intensity at 10-1 Torr is â¼25% of that observed in the absence of H2O. The formation of molecularly adsorbed H2O was also observed. Density functional theory-based calculations suggest favorable absorption energies for N2 bonding to both V(IV) and V(III) cation sites but less so for V(V) sites. Hartree-Fock-based cluster calculations for N2-V end-on adsorption show that experimental XPS doublet features are consistent with the calculated shake-up and normal, final ionic configurations for N2 end-on bonding to V(III) sites but not V(IV) sites. The XPS spectra of vanadium oxide transferred in situ between electrochemical and UHV environments indicate that the oxide surfaces studied here are stable upon exposure to the electrolyte under NRR-relevant conditions.
RESUMEN
Plasma modification of transition metal nitride/oxynitride (MOxNy) surfaces for enhanced surface properties is highly desirable, given the scalability of such methods and limitations of thermal treatments. In situ x-ray excited photoelectron spectroscopy demonstrates that the O2 plasma oxidation of VOxNy films generates non-lattice N1s surface features with binding energies near 396.5 eV, which are associated with the nitrogen reduction reaction activity but not observed upon thermal oxidation. The NH3 plasma generates N1s surface features near 400.5 eV binding energy. The O2+NH3 plasma generates both types of N1s features. Annealing in UHV to <1000 K reverses plasma-induced changes to N1s spectra. Density functional theory (DFT) calculations integrated with the experiments indicate that the plasma-induced N1s features at â¼396.5 eV and 400.5 eV are V≡N: and V-NH2 sites, respectively, with significantly lower thermal stabilities than lattice N sites. These results provide practical insight regarding the plasma modification of MOxNy surfaces for important applications.
RESUMEN
Metastasis is the leading cause of mortality in patients with solid tumors. In this regard, we previously reported that Pseudopodium-Enriched Atypical Kinase One (PEAK1) is necessary for non-canonical Transforming Growth Factor ß (TGFß) signaling and TGFß/fibronectin-induced metastasis. Here, we demonstrate that inhibition of DHPS-dependent eIF5A1/2 hypusination blocks PEAK1 and E-Cadherin expression, breast cancer cell viability and TGFß/fibronectin-induced PEAK1-dependent breast cancer metastasis. Interestingly, TGFß stimulation of high-grade metastatic breast cancer cells increases and sustains eIF5A1/2 hypusination. We used a suite of bioinformatics platforms to search biochemical/functional interactions and clinical databases for additional control points in eIF5A1/2 and PEAK1-Epithelial to Mesenchymal Transition (EPE) pathways. This effort revealed that interacting EPE genes were enriched for TP53 transcriptional targets and were commonly co-amplified in breast cancer patients harboring inactivating TP53 mutations. Taken together, these results suggest that combinatorial therapies targeting DHPS and protein activities elevated in TP53-mutant breast cancers may reduce systemic tumor burden and improve patient outcomes.
Asunto(s)
Neoplasias de la Mama/metabolismo , Fibronectinas/metabolismo , Oxidorreductasas actuantes sobre Donantes de Grupo CH-NH/metabolismo , Factores de Iniciación de Péptidos/metabolismo , Proteínas de Unión al ARN/metabolismo , Factor de Crecimiento Transformador beta/metabolismo , Proteína p53 Supresora de Tumor/genética , Neoplasias de la Mama/patología , Cadherinas/antagonistas & inhibidores , Cadherinas/genética , Cadherinas/metabolismo , Femenino , Guanina/análogos & derivados , Guanina/farmacología , Humanos , Oxidorreductasas actuantes sobre Donantes de Grupo CH-NH/antagonistas & inhibidores , Factores de Iniciación de Péptidos/antagonistas & inhibidores , Pronóstico , Proteínas Tirosina Quinasas/antagonistas & inhibidores , Proteínas Tirosina Quinasas/genética , Proteínas Tirosina Quinasas/metabolismo , Proteínas de Unión al ARN/antagonistas & inhibidores , Células Tumorales Cultivadas , Proteína p53 Supresora de Tumor/metabolismo , Factor 5A Eucariótico de Iniciación de TraducciónRESUMEN
Semiconducting boron carbides based on cross-linked carborane (B10C2H12) icosahedra, developed several decades ago, are of significant interest in a variety of emerging areas, including photocatalysis, spintronics, and especially neutron detection. These materials, however, display generally poor charge carrier mobility, high defect levels and other properties that pose significant drawbacks. A class of nanocomposite carborane-based materials has recently been developed, that addresses many of these issues. The films consist of polymerized mixtures of carboranes and aromatic species, including benzene, 1,4-diaminobenzene, pyridine or aniline. In these materials, electronic states corresponding to the aromatic moiety appearing near the top of the valence band, and states associated with the carborane moiety occupy the bottom of the conduction band. Band gap energies are substantially reduced relative to films without aromatic content. Transport measurements also indicate that charge scattering lifetimes are substantially enhanced in aromatic/carborane films compared to corresponding films without aromatic content. This combination of superior electron-hole separation, narrower band gaps, and superior charge scattering lifetimes, yields markedly enhanced charge collection in neutron voltaics studies compared to conventional carborane-derived boron carbides. The implications of these enhanced properties for neutron detection and other applications are discussed.
RESUMEN
The tumor microenvironment (TME) has been recognized as an integral component of malignancies in breast and prostate tissues, contributing in confounding ways to tumor progression, metastasis, therapy resistance and disease recurrence. Major components of the TME are immune cells, fibroblasts, pericytes, endothelial cells, mesenchymal stroma/stem cells (MSCs), and extracellular matrix (ECM) components. Herein, we discuss the molecular and cellular heterogeneity within the TME and how this presents unique challenges and opportunities for treating breast and prostate cancers.
RESUMEN
CRIPTO (CR-1, TDGF1) is a cell surface/secreted oncoprotein actively involved in development and cancer. Here, we report that high expression of CRIPTO correlates with poor survival in stratified risk groups of prostate cancer (PCa) patients. CRIPTO and its signaling partner glucose-regulated protein 78 (GRP78) are highly expressed in PCa metastases and display higher levels in the metastatic ALDHhigh sub-population of PC-3M-Pro4Luc2 PCa cells compared with non-metastatic ALDHlow. Coculture of the osteotropic PC-3M-Pro4Luc2 PCa cells with differentiated primary human osteoblasts induced CRIPTO and GRP78 expression in cancer cells and increases the size of the ALDHhigh sub-population. Additionally, CRIPTO or GRP78 knockdown decreases proliferation, migration, clonogenicity and the size of the metastasis-initiating ALDHhigh sub-population. CRIPTO knockdown reduces the invasion of PC-3M-Pro4Luc2 cells in zebrafish and inhibits bone metastasis in a preclinical mouse model. These results highlight a functional role for CRIPTO and GRP78 in PCa metastasis and suggest that targeting CRIPTO/GRP78 signaling may have significant therapeutic potential.
Asunto(s)
Neoplasias Óseas/secundario , Proteínas Ligadas a GPI/metabolismo , Proteínas de Choque Térmico/metabolismo , Péptidos y Proteínas de Señalización Intercelular/metabolismo , Proteínas de Neoplasias/metabolismo , Neoplasias de la Próstata/patología , Animales , Neoplasias Óseas/metabolismo , Línea Celular Tumoral , Movimiento Celular , Proliferación Celular , Chaperón BiP del Retículo Endoplásmico , Proteínas Ligadas a GPI/genética , Técnicas de Silenciamiento del Gen , Proteínas de Choque Térmico/genética , Humanos , Péptidos y Proteínas de Señalización Intercelular/genética , Estimación de Kaplan-Meier , Masculino , Ratones , Ratones Desnudos , Proteínas de Neoplasias/genética , Trasplante de Neoplasias , Neoplasias de la Próstata/genéticaRESUMEN
Pancreatic ductal adenocarcinoma (PDAC) is a deadly malignancy that affects nearly 50,000 patients each year. The overall 5-year survival rate for this malignancy remains the lowest of any cancer at around 7% due to limited diagnostic methods, disease aggressiveness and a lack of targeted therapeutic interventions. This review highlights the successes achieved over the past several decades as well as the significant cellular and molecular hurdles that remain in combatting this deadly disease at a translational level.
Asunto(s)
Carcinoma Ductal Pancreático/patología , Neoplasias Pancreáticas/patología , Animales , Carcinogénesis/metabolismo , Carcinogénesis/patología , Carcinoma Ductal Pancreático/etiología , Carcinoma Ductal Pancreático/mortalidad , Carcinoma Ductal Pancreático/terapia , Humanos , Mutación , Neoplasias Pancreáticas/etiología , Neoplasias Pancreáticas/mortalidad , Neoplasias Pancreáticas/terapiaRESUMEN
BACKGROUND: Calcitriol is widely used in conjunction with phosphorus-binders containing calcium to treat secondary hyperparathyroidism in dialysis patients. Its efficacy in patients with severe hyperparathyroidism is diminished, in part, due to glandular hyperplasia associated with decreased calcitriol and calcium receptors. SUBJECTS AND METHODS: We, therefore, developed a prospective, randomized trial comparing i.v. calcitriol plus calcium carbonate (CaCO3) compared to CaCO3 alone (control) in patients with mild to moderate hyperparathyroidism who were within the first year of initiating hemodialysis. Patients underwent calcium (Ca) suppression/stimulation testing at baseline and after six and twelve months of treatment to indirectly assess parathyroid gland hyperplasia. RESULTS: In the calcitriol group, the amino-terminal parathyroid hormone (N-PTH) decreased significantly from a baseline value of 70 +/- 12 pg/ml at month zero to 22 +/- 7 and 19 +/- 6 pg/ml at months 6 and 12, respectively (the conversion factor of amino-terminal PTH to intact PTH is 6, i.e., 10 pg/ml N-PTH equals 60 pg/ml intact PTH). In contrast, the N-PTH levels in the CaCO3 alone group did not change. The change in nadir N-PTH levels at month 12 compared to month zero decreased by 14 +/- 7% in the calcitriol group but increased by 96 +/- 59% in the control group (p < 0.05). In addition, the increment in N-PTH levels during hypocalcemic stimulation decreased by 68 +/- 6% at month 12 compared to month zero but increased by 61 +/- 42% in the control group. Although total calcium and phosphorus levels were not different between the two groups, ionized calcium values were higher in the calcitriol group. The incidence of hypercalcemia was the same in both groups and the episodes were asymptomatic. CONCLUSION: Pulse calcitriol therapy is effective in preventing progression of secondary hyperparathyroidism in hemodialysis patients with mild to moderate disease. Based on Ca suppression/stimulation tests, calcitriol was more successful in preventing gland growth than CaCO3 alone. Further studies are needed to determine if the strategy of early treatment of mild to moderate hyperparathyroidism by pulse calcitriol is safe and effective in hemodialysis in patients.
Asunto(s)
Calcitriol/uso terapéutico , Hiperparatiroidismo Secundario/tratamiento farmacológico , Diálisis Renal , Calcio/sangre , Humanos , Hiperparatiroidismo Secundario/sangre , Fósforo/sangre , Factores de TiempoRESUMEN
Cripto is a developmental oncoprotein that signals via mitogen-activated protein kinase (MAPK)/extracellular signal-regulated kinase (ERK), phosphatidylinositol 3-kinase (PI3K)/Akt and Smad2/3 pathways. However, the molecular basis for Cripto coupling to these pathways during embryogenesis and tumorigenesis is not fully understood. In this regard, we recently demonstrated that Cripto forms a cell surface complex with the HSP70 family member glucose-regulated protein-78 (GRP78). Here, we provide novel functional evidence demonstrating that cell surface GRP78 is a necessary mediator of Cripto signaling in human tumor, mammary epithelial and embryonic stem cells. We show that targeted disruption of the cell surface Cripto/GRP78 complex using shRNAs or GRP78 immunoneutralization precludes Cripto activation of MAPK/PI3K pathways and modulation of activin-A, activin-B, Nodal and transforming growth factor-beta1 signaling. We further demonstrate that blockade of Cripto binding to cell surface GRP78 prevents Cripto from increasing cellular proliferation, downregulating E-Cadherin, decreasing cell adhesion and promoting pro-proliferative responses to activin-A and Nodal. Thus, disrupting the Cripto/GRP78 binding interface blocks oncogenic Cripto signaling and may have important therapeutic value in the treatment of cancer.
Asunto(s)
Factor de Crecimiento Epidérmico/metabolismo , Proteínas de Choque Térmico/metabolismo , Glicoproteínas de Membrana/metabolismo , Proteínas Quinasas Activadas por Mitógenos/metabolismo , Proteínas de Neoplasias/metabolismo , Fosfatidilinositol 3-Quinasas/metabolismo , Transducción de Señal/fisiología , Proteínas Smad/metabolismo , Activinas/farmacología , Anticuerpos/farmacología , Western Blotting , Cadherinas/metabolismo , Adhesión Celular/efectos de los fármacos , Línea Celular , Línea Celular Tumoral , Proliferación Celular/efectos de los fármacos , Chaperón BiP del Retículo Endoplásmico , Factor de Crecimiento Epidérmico/genética , Proteínas Ligadas a GPI , Proteínas de Choque Térmico/genética , Proteínas de Choque Térmico/inmunología , Humanos , Inmunoprecipitación , Péptidos y Proteínas de Señalización Intercelular , Luciferasas/genética , Luciferasas/metabolismo , Glicoproteínas de Membrana/genética , Microscopía Confocal , Modelos Biológicos , Proteínas de Neoplasias/genética , Unión Proteica/efectos de los fármacos , ARN Interferente Pequeño/genética , Ensayo de Unión Radioligante , Transducción de Señal/efectos de los fármacos , Proteína Smad2/metabolismo , Proteína smad3/metabolismoRESUMEN
The effectiveness of hemodialysis depends, in part, on the delivery of the prescribed rate of blood flow and the amount of blood recirculation. Studies evaluating the magnitude of recirculation in double-lumen catheters at blood flow rates > or = 300 mL/min have not been performed. We therefore examined the effects of prescribed blood flow rate and placement site on measure blood flow, recirculation and effective clearance using double-lumen catheters in 17 patients. Double-lumen catheters were placed in the internal jugular (12.5 cm), subclavian (20 cm), and femoral veins (15 cm and 24 cm). Recirculation studies were performed in triplicate with a two-needle method at blood flow rates of 250, 300, 350, and 400 mL/min. Blood flow rate was measured with an ultrasonic flow meter placed on the venous line. The arterial line pressure was continuously monitored. Mean arterial line pressure was -105 +/- mm Hg at 250 mL/min and -231 +/- mm Hg at 400 mL/min prescribed blood flow rates in the internal jugular, subclavian, and 15-cm femoral vein catheters. Patients with 24-cm femoral catheters had a mean arterial line pressure of -196 +/- mm Hg at 250 mL/min and -327 +/- mm Hg at 400 mL/min. In spite of the change in arterial line pressure, measured blood flow rate increased appropriately at all set blood flows and with all catheter sites studied.(ABSTRACT TRUNCATED AT 250 WORDS)
Asunto(s)
Circulación Sanguínea , Velocidad del Flujo Sanguíneo , Cateterismo/instrumentación , Tasa de Depuración Metabólica , Diálisis Renal/instrumentación , Adulto , Vena Femoral , Humanos , Venas Yugulares , Persona de Mediana Edad , Vena Subclavia , Factores de TiempoRESUMEN
It has been suggested that magnesium carbonate (MgCO3) may be an effective and safe alternative to calcium carbonate in binding phosphorus in dialysis patients. In these studies, the concentration of magnesium in the dialysate was either very low or zero. To date, only patients undergoing conventional dialysis have been reported. The primary purpose of the present study was to determine the fluxes of magnesium using dialysate magnesium concentrations of 0 mg/dL, 0.6 mg/dL, and 1.8 mg/dL in eight patients undergoing high-efficiency hemodialysis. The net removal of magnesium was 486 +/- 44 mg, 306 +/- 69 mg, and 56 +/- 50 mg, with the use of dialysate magnesium concentrations of 0 mg/dL, 0.6 mg/dL, and 1.8 mg/dL, respectively (P = 0.001). Plasma magnesium levels significantly decreased from 3.3 +/- 0.2 mg/dL to 1.6 +/- 0.2 mg/dL and from 3.4 +/- 0.3 mg/dL to 2.1 +/- 0.2 mg/dL during the dialysis sessions using 0 mg/dL and 0.6 mg/dL magnesium dialysates, respectively. Plasma magnesium remained unchanged when 1.8 mg/dL dialysate magnesium was used. A significant independent correlation was found between the total magnesium removed and both the dialysate concentration used (P < 0.001) and the predialysis plasma magnesium level (P < 0.001). The measured magnesium removal exceeded the estimated predialysis extracellular fluid (ECF) magnesium pool with the use of magnesium-free dialysate. This was not found with dialysate magnesium concentrations of either 0.6 mg/dL or 1.8 mg/dL. A secondary purpose of the study was to determine the acute clinical tolerance of the low and magnesium-free dialysates.(ABSTRACT TRUNCATED AT 250 WORDS)
Asunto(s)
Soluciones para Diálisis/química , Magnesio/administración & dosificación , Magnesio/análisis , Diálisis Renal , Administración Oral , Análisis de Varianza , Femenino , Humanos , Enfermedades Renales/sangre , Enfermedades Renales/terapia , Modelos Lineales , Magnesio/sangre , Factores de TiempoRESUMEN
The effects of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors on the metabolism of apolipoprotein (apo) B-containing lipoproteins appear to differ according to the predominant lipoprotein profiles present and the condition being treated. In familial hypercholesterolemia, with isolated low density lipoprotein (LDL) elevations, the LDL-apoB elimination rate is increased by up-regulated LDL-receptors. In familial combined hyperlipidemia where very low density lipoprotein (VLDL) and LDL both may be increased and enhanced production of LDL-apoB may be present, HMG-CoA reductase inhibitors seem to diminish increased LDL-apoB production. The drug-induced decreases in LDL-apoB production could be due to decreased production of precursor VLDL-apoB or due to decreased conversion of VLDL-apoB to LDL-apoB after enhanced removal of VLDL by up-regulated LDL-receptors. To distinguish between these possibilities, we assessed the effects of HMG-CoA reductase inhibitors in another condition in which there is both apoB overproduction and accumulation of VLDL and LDL in plasma, the nephrotic syndrome. We used endogenous labeling of apoB with [13C]leucine and a multicompartmental model to calculate the metabolic parameters of apoB-containing lipoproteins. Only subjects with focal segmental glomerular sclerosis (FSGS) were included, as FSGS is a chronic, very slowly progressive form of nephrotic syndrome. A double-blind, randomized, placebo-controlled, crossover design was used. Treatment periods of 6 weeks were separated by a 2-week washout period. Of the four men studied, three had high triglyceride levels and four had high cholesterol levels. Lovastatin (20 mg/day) significantly decreased cholesterol (27.6 +/- 6%), LDL-cholesterol (27.6 +/- 9%) and plasma apoB (17.9 +/- 2.9%) (P < 0.01 for all). During the placebo period, calculation of kinetic parameters revealed VLDL-, intermediate density lipoprotein (IDL)-, and LDL-apoB overproduction and decreased VLDL-apoB fractional catabolic rate. Lovastatin significantly decreased LDL-apoB production rate in all cases (34.1 +/- 14%, P = 0.03). The decreased LDL-apoB was mainly due to a channelling of LDL precursors away from conversion to LDL (conversion of VLDL to LDL decreased from 80.6 +/- 8.3% to 55.9 +/- 17.2%, P = 0.05). Thus, lovastatin decreased LDL-cholesterol in nephrotic subjects mainly by inhibiting LDL-apoB production from VLDL.
Asunto(s)
Glomeruloesclerosis Focal y Segmentaria/complicaciones , Hiperlipidemias/tratamiento farmacológico , Lovastatina/uso terapéutico , Apolipoproteínas/sangre , Apolipoproteínas B/biosíntesis , LDL-Colesterol/sangre , Método Doble Ciego , Humanos , Hiperlipidemias/sangre , Hiperlipidemias/etiología , Cinética , Lípidos/sangre , Lipoproteínas/sangre , Lipoproteínas IDL , Lipoproteínas LDL/sangre , Lipoproteínas VLDL/sangre , Lovastatina/farmacología , Masculino , Placebos , Triglicéridos/sangreRESUMEN
The use of calcium carbonate (CaCO3) to bind phosphorus (P) in chronic hemodialysis patients has been a popular tactic in the past decade. Nonetheless, problems with hypercalcemia decrease its usefulness, particularly in patients treated with calcitriol. A P binder not containing calcium (Ca) would be of value in these circumstances. In short-term studies, we showed that magnesium carbonate (MgCO3) was well-tolerated and controlled P and Mg levels when given in conjunction with a dialysate Mg of 0.6 mg/dl. We, therefore, performed a prospective, randomized, crossover study to evaluate if the chronic use of MgCO3 would allow a reduction in the dose of CaCO3 and yet achieve acceptable levels of Ca, P, and Mg. We also assessed whether the lower dose of CaCO3 would facilitate the use of larger doses of calcitriol. The two phases were MgCO3 plus half the usual dose of CaCO3 and CaCO3 alone given in the usual dose. It was found that MgCO3 (dose, 465 +/- 52 mg/day elemental Mg) allowed a decrease in the amount of elemental Ca ingested from 2.9 +/- 0.4 to 1.2 +/- 0.2 g/day (P < 0.0001). The Ca, P, Mg levels were the same in the two phases. The maximum dose of i.v. calcitriol without causing hypercalcemia was 1.5 +/- 0.3 micrograms/treatment during the MgCO3 phase and 0.8 +/- micrograms/treatment during the Ca phase (P < 0.02). If these studies are confirmed, the use of MgCO3 and a dialysate Mg of 0.6 mg/dl may be considered in selected patients who develop hypercalcemia during treatment with i.v. calcitriol and CaCO3.